Tag Archives: seriously ill children

Business

URALCHEM and the Ziedot.lv Fund present New Year Gifts to seriously ill children in Latvia

Leave a comment

URALCHEM and a leading Latvian charity organization, the Ziedot.lv Fund, held New Year activities and events for a group of seriously ill children in Latvia and members of their families. URALCHEM’s CEO, Dmitry Konyaev, and the head of the Ziedot.lv Fund, Ruta Dimanta, gave presents to the children.

Riga, Latvia – December 20, 2012 — URALCHEM and a leading Latvian charity organization, the Ziedot.lv Fund, held New Year activities and events for a group of seriously ill children in Latvia and members of their families. URALCHEM’s CEO, Dmitry Konyaev, and the head of the Ziedot.lv Fund, Ruta Dimanta, gave presents to the children. These children are beneficiaries of a joint charity programme “Help for seriously ill children”, which was launched in the autumn of this year.

In September 2012, URALCHEM and the Ziedot.lv Fund signed an agreement that started a charitable programme for the treatment of 20 children from Latvia in leading Russian clinics. URALCHEM is providing total funding to the amount of €80 thousand.

Since the launch of the programme, 11 families have received help with specific treatment or rehabilitation for their children using leading Russian clinics. The Ziedot.lv Fund has selected clinics and treatment programmes on the basis of doctors’ recommendations and requests from parents for financial assistance. URALCHEM has currently provided €25 thousand of funding.

Dmitry Konyaev came to Latvia to show his support for the children and give them New Year presents. “We are pleased that the company’s social policy in Latvia is generating results already. Together with the Ziedot.lv Fund, we intend to continue our support for the children. They are now on their way to recovery and I wish them success in the coming year in overcoming their problems,” he said.

Ruta Dimanta said that the Fund treated every case individually, choosing leading medical institutions in Russia to carry out the treatments. In clinical cases involving children with rare or complex conditions requiring care outside Latvia and not funded by the state, URALCHEM’s participation enables the provision of hospital and other treatment and support for the children’s’ families. She added, “The condition of the children who have been helped has improved significantly. We are grateful to the Russian doctors and to URALCHEM for their assistance. Our joint programme is gaining momentum and I hope that as a result, next year more families will be able to celebrate this holiday with joy.”

-Ends-

Public Relations Department
URALCHEM, OJSC
Tel: +7 (495) 721 89 89
E-Mail: pr@URALCHEM.com
Web: http://www.uralchem.com

URALCHEM, OJSC is one of the largest producers of nitrogen and phosphate fertilisers in Russia and the CIS with production capacities of over 2.5 million tonnes of ammonium nitrate, 2.8 million tonnes of ammonia, 0.8 million tonnes of MAP and DAP, 0.8 million tonnes of complex fertilisers and 1.2 million tonnes of urea. URALCHEM, OJSC is the second largest ammonium nitrate producer in the world and number one in Russia, the second largest producer of nitrogen fertilisers in Russia. Key production assets of URALCHEM, OJSC include Azot Branch of URALCHEM, OJSC in Berezniki, Perm Region; OJSC Minudobrenia, Perm; MFP Kirovo-Chepetsk Chemical Works, OJSC Branch in Kirovo-Chepetsk, Kirov region; Voskresensk Mineral Fertilisers, OJSC in Voskresensk, Moscow region.

Some of the information in this press release may contain projections or other forward-looking statements regarding future events or the future financial performance of URALCHEM. We wish to caution you that these statements are only predictions. We do not intend to update these statements and our actual results may differ materially from those contained in our projections or forward-looking statements, including, among others, the achievement of anticipated levels of profitability, growth, cost and synergy of our recent acquisitions, the impact of competitive pricing, the ability to obtain necessary regulatory approvals and licenses, the impact of developments in the Russian economic, political and legal environment, financial risk management and the impact of general business and global economic conditions.

Business

URALCHEM and the Ziedot.lv Fund combine to help seriously ill children in Latvia

Leave a comment

URALCHEM and the fund of Ziedot.lv, have agreed to work together to help seriously ill children who need specific treatment or rehabilitation using leading Russian clinics.

Riga, Latvia – October 3, 2012 — URALCHEM and a leading charitable organization of Latvia, the fund of Ziedot.lv, have agreed to work together to help seriously ill children who need specific treatment or rehabilitation using leading Russian clinics. URALCHEM will provide funding for the hospitalization and treatment of children to the amount of 80 thousand Euros. A corresponding agreement has been signed today by URALCHEM CEO Dmitry Konyaev and Manager of the Fund Ziedot.lv Ruta Dimanta.

Dmitry Konyaev, CEO of URALCHEM, OJSC:

“Since 2009, URALCHEM has been implementing a large-scale logistics project involving the creation of a terminal for transhipment of mineral fertilizers in the Latvian port of Riga. Traditionally, in all regions where URALCHEM does business, we pursue a socially responsible policy, which aims to address the socio-economic problems of the people of these regions. One of the priorities of our policy has always been to help children. In a joint program with Ziedot.lv we will help families of different nationalities living in Latvia who need financial and medical assistance.”

Ruta Dimanta, Head of the Fund Ziedot.lv:

“The programme will help seriously ill children who need treatment in Russian clinics, and whose families are not able to cover all the costs. URALCHEM’s support is particularly important because the treatment of Latvian residents outside the European Union is not funded by the state. In practice, in cases with rare or complex diseases, it is necessary to seek help outside Latvia. Children deserve to have the highest level of treatment based on modern scientific developments.”

The agreement stipulates that, within a specially designed charity programme – “Help for seriously ill children”, 20 children from Latvia will be treated in leading medical institutions in Russia during the coming year. The programme participants are selected by the fund Ziedot.lv on the basis of doctor’s recommendations and requests from parents for financial assistance. Assistance is needed in the treatment of diseases such as autism, vision recovery, cerebral palsy and developmental delay.

With this initiative by URALCHEM, Latvian children will now be able to access world leading medical treatment not only within the EU but in Russia as well.

-Ends-

Public Relations Department
URALCHEM, OJSC
Tel: +7 (495) 721 89 89
E-Mail: pr@URALCHEM.com
Web: http://www.uralchem.com

URALCHEM, OJSC is one of the largest producers of nitrogen and phosphate fertilisers in Russia and the CIS with production capacities of over 2.5 million tonnes of ammonium nitrate, 2.8 million tonnes of ammonia, 0.8 million tonnes of MAP and DAP, 0.8 million tonnes of complex fertilisers and 1.2 million tonnes of urea. URALCHEM, OJSC is the second largest ammonium nitrate producer in the world and number one in Russia, the second largest producer of nitrogen fertilisers in Russia. Key production assets of URALCHEM, OJSC include Azot Branch of URALCHEM, OJSC in Berezniki, Perm Region; OJSC Minudobrenia, Perm; MFP Kirovo-Chepetsk Chemical Works, OJSC Branch in Kirovo-Chepetsk, Kirov region; Voskresensk Mineral Fertilisers, OJSC in Voskresensk, Moscow region.

Some of the information in this press release may contain projections or other forward-looking statements regarding future events or the future financial performance of URALCHEM. We wish to caution you that these statements are only predictions. We do not intend to update these statements and our actual results may differ materially from those contained in our projections or forward-looking statements, including, among others, the achievement of anticipated levels of profitability, growth, cost and synergy of our recent acquisitions, the impact of competitive pricing, the ability to obtain necessary regulatory approvals and licenses, the impact of developments in the Russian economic, political and legal environment, financial risk management and the impact of general business and global economic conditions.